• Explore /
  • Poster
  • / A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).

A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).

Abstract Poster

Authors

null

Emanuela Risi

Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy

Emanuela Risi , Chiara Biagioni , Matteo Benelli , Ilenia Migliaccio , Amelia McCartney , Martina Bonechi , Cristina Guarducci , Florentine Hilbers , Serena Di Cosimo , Jose Baselga , Dario Romagnoli , Giulia Boccalini , Stefania Vitale , Andrea Grilli , Silvio Bicciato , Christos Sotiriou , Laura Biganzoli , Angelo Di Leo , Luca Malorni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 36, 2018 (suppl; abstr 570)

DOI

10.1200/JCO.2018.36.15_suppl.570

Abstract #

570

Poster Bd #

62

Abstract Disclosures

Similar Posters

First Author: Christian F. Singer

First Author: Ning Liao

First Author: Aleix Prat

First Author: Christian Eichler